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Key messages: 
1. Abdominal enterocutaneous fistula (ECF) in Crohn’s disease most often 
occur postoperative after bowel resection. 
2. Prior to operative treatment, maximal medical therapy is warranted. 
3. Definitive surgery is generally delayed for several months (>6 months), 
until both local and systemic conditions have been optimized. 
4. Successful surgery requires the resection to the ECF and associated bowel. 
5. Owing to the intrinsic bowel pathology and the poor quality of the 
abdominal wall due to multiple abdominal operations, the ECF recur-
rence rate remains high.
Learning objectives: 
1. To describe the principles of multidisciplinary management of Crohn’s 
patients with abdominal enterocutaneous fistulas. 
2. To understand the timing and techniques of surgical treatment options. 
Abstract: 
Introduction 
Abdominal enterocutaneous fistulas (ECFs) cause significant morbidity and 
mortality for all patients, including those with inflammatory bowel disease 
(IBD), and represent a challenging management issue. It is estimated that 
75-85% of ECF form after operation as a result of bowel injury, inadvertent 
enterotomy and/or anastomotic leakage. The remaining 15%-25% form 
spontaneously secondary to underlying pathology; Crohn’s disease (CD) 
being the commonest cause in the developed world.
1. Approximately 15-20% of IBD patients, mostly those with CD, develop 
ECF during their lifetime.
2. Crohn’s ECF most often occur after surgical resection (anastomotic leak 
or recurrence) or spontaneously. The St. Marks reported on 277 ECF, 
whereas 111 were CD-related (68% postoperative, 30% spontaneous 
and 2% after radiological drainage).
3. Published studies of surgical treatment of EHC are very heterogeneous 
as results of Crohn’s and non-Crohn’s ECF are were rarely reported 
separately. The aim of this article is to review the current surgical 
literature on ECF focusing on Crohn’s abdominal ECF. 
Maximal medical therapy 
Prior to embarking on operative treatment, maximal medical therapy is 
warranted. Infliximab, has been shown to effectively induce closure of 
perianal fistulas in 55% of patients after 3 doses.4. In another study includ-
ing 26 fistula patients 54% needed surgery despite therapy with infliximab. 
None of the ECF in this study responded to the biologic therapy.5 However, 
despite its success, over 50% of patients (abdominal>perineal ECF) will 
eventually require surgical intervention and resection. Spontaneous healing 
is unlikely where there is an associated abscess cavity. 
Assessment of ECF 
There is no universally accepted classification for abdominal ECF. Charac-
terization is usually made on the basis of anatomy (site of origin, simple 
or complex fistula, end or lateral fistula, and presence or absence of distal 
obstruction) or fistula output (with high output usually defined as more 
than 500ml per 24h). The exact anatomy of ECF is usually delineated by a 
combination of clinical observation, biochemical analysis of fistula effluent 
and radiological investigation (contrast CT and MRI). 
Crohn’s disease ECFs require a multidisciplinary approach and a team of 
specialized individuals including the surgeon, gastroenterologist, inter-
ventional radiologist, dietician and most importantly a dedicated wound 
ostomy nurse. Patients may have multiple external openings, bridges of 
intervening healthy skin, and prior abdominal scars that make proper 
pouching extremely difficult. Protection of the skin is a vital early step in the 
management of ECF. 
Pre-Surgery treatment 
A useful acronym to apply to the management of Crohn’s ECF patients is 
“SNAP”, representing management of Sepsis and Skin care, Nutritional 
support, definition of intestinal Anatomy, and development of a surgical 
Procedure to deal with the fistula. 
Initial fistula management should include controlling ECF effluent by 
pouching and skin protection. Early and aggressive treatment of sepsis is 
very important, as sepsis caused the majority of death (23/30 patients in the 
St. Marks experience).3 Similarly, adequate nutritional support is recog-
nized as a key factor in reducing the mortality. There is ongoing discussion 
about the best route of nutrition.1 It has been suggested that parenteral 
nutrition may decrease small bowel secretions and so not only decrease 
fistula output but also possibly increase the likelihood of spontaneous clo-
sure. However, there have been no randomized trials comparing enteral to 
parenteral nutrition. It is our policy to use enteral nutrition as early as pos-
sible to prevent bacterial translocation and to maintain immune function. 
Surgical procedures for intestinal reconstruction should be deferred until 
both local and systemic conditions have been optimized and should be 
avoided in the presence of significant (<30 g/l) hypoalbuminemia. Definitive 
surgery is generally delayed for several months, until physiologic deficits 
have been restored and intra-abdominal conditions are less hostile. Initial 
surgery was delayed for 5.8 month and a median of 3 operative procedures 
were necessary to achieve healing in a study of 95 Crohn’s ECFs.4 
Surgical strategies 
Successful surgery requires the resection to the ECF and associated bowel. 
The Cleveland Clinic evaluated various techniques for definitive treatment 
of ECF. A resection of the diseased bowel was associated with a significant 
lower recurrence rate (15%; 12 of 83 patients) compared to oversowing 
(75%; 9/12 patients, p<0.001) in Crohn’s ECF. Crohn’s disease by itself did 
not influence recurrence, whereas oversowing and wedge resection were 
independent predictors of recurrence.4 After the bowel is reanastomosed, it 
should be separated, if possible, from the abdominal wall with omental fat. 
For complex ECF there is often a significant portion of the abdominal wall 
that needs to be resected. The Mayo Clininc reported on 11 patients where 
a human acellular dermal matrix (hADM) was used to reconstruct the de-
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fect.6 After a mean follow-up of 1 year ±118 days, 10 of 11 patients remained 
free of ECF while on a general oral diet. Only 2 of the 11 patients stayed on 
medical therapy. Although hADM is an expensive material ($4’100 for a 
single 12x12cm sheet), these results justify its use because refractory ECF 
and the associated long-term cost of dealing with the complications in this 
high-risk population is far greater. Successful reconstructions of the abdom-
inal wall have also been reported using an island pedicled anterolateral 
thigh flap.7 
The healing rate after definitive surgery, delayed for a median of 8 months 
(1-180), was 82% in a large series of the St. Mark’s Hospital, although more 
than one attempt was required in some patients.3 Successful healing was 
reported in 35/55 patients (63%) in the only prospective study published, 
where 35% were Crohn’s ECF.8 Owing to the intrinsic bowel pathology and 
the poor quality of the abdominal wall due to multiple abdominal opera-
tions, the ECF recurrence rate remains high.4 
Combined medical-surgical approach 
A small case series of three patients treated with a combined approach 
of Infliximab 5mg/kg two month prior to surgery and maintenance after 
resection and reconstruction demonstrated healing in all three cases.9 The 
use of infliximab (within 12 weeks prior to surgery) was not associated with 
an increased risk of surgical complications in several studies.10, 11. How-
ever, one study demonstrated a higher readmission rate.12 In the absence 
of abscess a combined surgical-medical approach with TNF-α antagonist 
(stopped 8-12 weeks prior to major abdominal surgery) seems to be a valu-
able option for Crohn’s patients with ECF. 
Malignant transformation
Malignant transformation of perianal and ECF is very rare and occurred only 
in 4 out of 6`058 CD patients (prevalence of 0.004%) after a follow-up of 17 
years. The malignancies developed 25 years (IQR 10-38) after CD diagnosis 
and 10 years (IQR 6-22) after fistula diagnosis.13 
Future perspectives 
In a phase I study four patients with Crohn’s ECF have been injected with 
expanded adipose-derived stem cells. At one year 75% were successful, 
with complete re-epithelialization of the external opening at week 8.14 
These data are promising, but need to be confirmed in controlled trials. 
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